Human papillomavirus (HPV) types 6 and 11 can infect the squamous epithelium of the
respiratory tract. Up to 8· 9% of patients with HPV-associated recurrent respiratory …

Objective To evaluate the safety, immunogenicity, and efficacy of INO‐3107, a DNA
immunotherapy designed to elicit targeted T‐cell responses against human papillomavirus …

Objectives Pulmonary papillomatosis is a rare but severe manifestation of recurrent
respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP …

Objective The clinical course of recurrent respiratory papillomatosis (RRP) varies from
spontaneous remission to severe airway obstruction with wide variability in recurrence …

Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP)
including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic …

Background Recurrent respiratory papillomatosis (RRP) is a currently incurable benign
neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice …

Objectives Medical therapies to limit disease recurrence are critically needed for recurrent
respiratory papillomatosis (RRP). Systemic bevacizumab is emerging as an exciting …

Introduction In the past two decades, laser systems were introduced into the office setting for
laryngeal pathologies, offering the advantages of a shorter procedure and recovery. To date …

Recurrent respiratory papillomatosis (RRP) is the most common benign pediatric laryngeal
neoplasm. Various adjuvant medical therapies have failed to reliably decrease surgical …

Papillomaviruses are extremely widespread, small, nonenveloped, icosahedral, species-
specific, double-stranded DNA epitheliotropic viruses, which include human …